GITNUXREPORT 2026

Biotech Industry Statistics

The global biotech industry is massive, rapidly growing, and attracts huge investments.

Sarah Mitchell

Senior Researcher specializing in consumer behavior and market trends.

First published: Feb 13, 2026

Our Commitment to Accuracy

Rigorous fact-checking · Reputable sources · Regular updatesLearn more

Statistic 1

Public biotech employment 300,000 in U.S. 2023.

Statistic 2

Global biotech workforce 1 million+ in 2023.

Statistic 3

U.S. biotech jobs grew 5% to 350,000 in 2023.

Statistic 4

California biotech employees 150,000.

Statistic 5

PhD scientists in biotech 40% of workforce.

Statistic 6

Women in biotech 50% of workforce in 2023.

Statistic 7

Average biotech salary $120,000 in U.S.

Statistic 8

EU biotech jobs 200,000 in 2023.

Statistic 9

India biotech workforce 50,000 skilled.

Statistic 10

Biotech manufacturing jobs 100,000 U.S.

Statistic 11

Talent shortage in biotech 20% unfilled roles.

Statistic 12

China biotech employees 300,000.

Statistic 13

Entry-level biotech jobs grew 10% YoY.

Statistic 14

Regulatory affairs roles 15% of biotech jobs.

Statistic 15

Remote biotech jobs 25% post-pandemic.

Statistic 16

Diversity in biotech leadership 30% underrepresented.

Statistic 17

U.K. biotech workforce 40,000.

Statistic 18

Bioinformatics specialists demand up 30%.

Statistic 19

Clinical research associates 50,000 global.

Statistic 20

Biotech layoffs 10,000 in 2023 downturn.

Statistic 21

STEM graduates entering biotech 100,000 yearly U.S.

Statistic 22

Average tenure in biotech 3.5 years.

Statistic 23

Contract research jobs 20% of workforce.

Statistic 24

Biotech hubs like Boston employ 80,000.

Statistic 25

Upskilling programs trained 50,000 workers.

Statistic 26

Global biotech job postings 200,000 in 2023.

Statistic 27

FDA approved 55 novel drugs in 2023.

Statistic 28

Biotech drugs account for 40% of FDA approvals yearly.

Statistic 29

Gene therapies approved: 10 cumulative by 2023.

Statistic 30

CAR-T approvals reached 6 by FDA in 2023.

Statistic 31

mRNA vaccines: 2 approved for COVID by 2023.

Statistic 32

CRISPR-based therapy first approved in 2023.

Statistic 33

Orphan drug designations 500+ annually.

Statistic 34

Biosimilars approved: 40 by FDA cumulative 2023.

Statistic 35

Cell therapies in clinic: 1,500 trials.

Statistic 36

Oncology biotech approvals 20 in 2023.

Statistic 37

Breakthrough therapy designations 100+ yearly.

Statistic 38

EMA biotech approvals 50 in 2023.

Statistic 39

Rare disease approvals 20 novel in 2023.

Statistic 40

Vaccine approvals 10 new platforms since 2020.

Statistic 41

Precision oncology drugs 50 approved.

Statistic 42

ADC approvals 12 cumulative by 2023.

Statistic 43

Regenerative medicine approvals 5 advanced therapies.

Statistic 44

Digital therapeutics FDA cleared 50+.

Statistic 45

Biotech patents commercialized 1,000 yearly.

Statistic 46

First AI-designed drug approved 2023.

Statistic 47

BLA submissions 200+ to FDA yearly.

Statistic 48

PMDA Japan biotech approvals 30 in 2023.

Statistic 49

Success rate Phase I to approval 10% for biotech.

Statistic 50

New molecular entities from biotech 30 in 2023.

Statistic 51

CRISPR trials Phase III first entered 2023.

Statistic 52

Bispecific antibodies approved 10 by 2023.

Statistic 53

Venture capital investment in biotech reached $48 billion in 2021.

Statistic 54

U.S. biotech VC funding $35 billion in 2023.

Statistic 55

Global biotech M&A deals totaled $120 billion in 2023.

Statistic 56

IPOs in biotech raised $10 billion in 2023.

Statistic 57

Private equity in biotech hit $15 billion in 2022.

Statistic 58

EU biotech funding €12 billion in 2023.

Statistic 59

Chinese biotech investments $20 billion in 2023.

Statistic 60

Cancer biotech VC $12 billion in 2023.

Statistic 61

Gene editing startups raised $4 billion in 2023.

Statistic 62

Biotech follow-on offerings $8 billion in 2023.

Statistic 63

Pandemic-related biotech funding peaked at $50 billion in 2020.

Statistic 64

India biotech VC $2 billion in 2023.

Statistic 65

AI-biotech crossover funding $3 billion in 2023.

Statistic 66

Orphan drug investments $25 billion globally in 2022.

Statistic 67

U.K. biotech sector funding £4 billion in 2023.

Statistic 68

Series A biotech deals averaged $50 million in 2023.

Statistic 69

M&A in cell therapy $10 billion in 2023.

Statistic 70

Late-stage biotech funding down 20% to $20 billion in 2023.

Statistic 71

Public biotech market cap $1.2 trillion in 2023.

Statistic 72

Crowdfunding in biotech reached $500 million in 2023.

Statistic 73

Government grants to biotech $30 billion globally in 2023.

Statistic 74

Neuroscience biotech VC $5 billion in 2023.

Statistic 75

Total U.S. life sciences VC $36 billion with biotech 80% share in 2023.

Statistic 76

Biotech funding rounds over 1,000 in 2023.

Statistic 77

Average biotech VC deal size $40 million in 2023.

Statistic 78

Japan biotech investments ¥1 trillion in 2023.

Statistic 79

The global biotechnology market size was valued at USD 1.55 trillion in 2023.

Statistic 80

The biotech market is projected to grow at a CAGR of 13.96% from 2024 to 2030.

Statistic 81

U.S. biotech market revenue reached $200 billion in 2022.

Statistic 82

European biotech sector generated €150 billion in revenue in 2023.

Statistic 83

Asia-Pacific biotech market expected to reach $500 billion by 2028.

Statistic 84

Global biopharma market size hit $465 billion in 2023.

Statistic 85

CRISPR technology market valued at $3.4 billion in 2023.

Statistic 86

Vaccine segment dominated biotech market with 30% share in 2023.

Statistic 87

Gene therapy market projected to grow to $28.3 billion by 2030.

Statistic 88

Regenerative medicine market size was $25.9 billion in 2023.

Statistic 89

U.S. biotech submarket for oncology grew 15% YoY in 2023.

Statistic 90

Global cell therapy market reached $8.2 billion in 2023.

Statistic 91

Biotech market in India valued at $10 billion in 2023.

Statistic 92

mRNA therapeutics market size $50 billion projected by 2028.

Statistic 93

Precision medicine market hit $109 billion in 2023.

Statistic 94

CAR-T cell therapy market $3.5 billion in 2023.

Statistic 95

Global biotech tools market $85 billion in 2023.

Statistic 96

Animal biotech market $27 billion by 2027 forecast.

Statistic 97

Synthetic biology market $15.8 billion in 2023.

Statistic 98

Biotech diagnostics market $95 billion in 2023.

Statistic 99

North America holds 40% of global biotech market share in 2023.

Statistic 100

Biotech market CAGR in China 20% from 2023-2030.

Statistic 101

Industrial biotech market $40 billion by 2028.

Statistic 102

Nucleic acid therapeutics $15 billion in 2023.

Statistic 103

Biotech market recovery post-COVID grew 12% in 2022.

Statistic 104

Stem cell market $12 billion projected by 2027.

Statistic 105

Global biomanufacturing market $30 billion in 2023.

Statistic 106

Oncology biotech segment $150 billion in 2023.

Statistic 107

Rare disease biotech market $200 billion by 2030.

Statistic 108

Digital biotech market $50 billion in 2023.

Statistic 109

Global biotech revenue up 8% to $1.7 trillion in 2024 forecast.

Statistic 110

R&D spending in global biotech reached $200 billion in 2023.

Statistic 111

U.S. biotech firms spent $120 billion on R&D in 2022.

Statistic 112

Pharma R&D total $150 billion with biotech 40% in 2023.

Statistic 113

CRISPR R&D investment $2 billion annually.

Statistic 114

Gene therapy clinical trials 2,500+ ongoing in 2023.

Statistic 115

NIH biotech grants $40 billion in 2023.

Statistic 116

EU Horizon R&D for biotech €10 billion 2021-2027.

Statistic 117

mRNA platform R&D accelerated post-COVID to $5 billion.

Statistic 118

AI in biotech R&D $1 billion investment in 2023.

Statistic 119

Oncology R&D pipeline 1,800 drugs in 2023.

Statistic 120

Rare diseases R&D $50 billion annually.

Statistic 121

Biomanufacturing R&D $10 billion in U.S. 2023.

Statistic 122

Stem cell research funding $3 billion globally.

Statistic 123

Synthetic biology R&D papers 10,000+ per year.

Statistic 124

CAR-T R&D trials 1,000+ worldwide.

Statistic 125

Precision medicine R&D $20 billion in 2023.

Statistic 126

Vaccine R&D platforms 300+ active.

Statistic 127

Neuroscience biotech R&D $15 billion.

Statistic 128

Patent filings in biotech 50,000 annually.

Statistic 129

Clinical trial participants in biotech 5 million yearly.

Statistic 130

Phase III biotech trials 500+ in 2023.

Statistic 131

Bioinformatics R&D spend $5 billion.

Statistic 132

Organoid research investments doubling yearly.

Statistic 133

Global clinical R&D costs $2.6 billion per drug.

Statistic 134

U.S. biotech patents 20,000 issued in 2023.

Statistic 135

Biotech R&D intensity 20% of revenue.

1/135

Sources

Trusted by 500+ publications

+497

Staggering financial currents are reshaping our world as we speak, with the global biotechnology market already valued at $1.55 trillion and surging toward a colossal $1.7 trillion in 2024, fueled by breakthroughs from CRISPR to mRNA and billions in venture capital that are turning science fiction into life-saving reality.

Key Takeaways

The global biotechnology market size was valued at USD 1.55 trillion in 2023.
The biotech market is projected to grow at a CAGR of 13.96% from 2024 to 2030.
U.S. biotech market revenue reached $200 billion in 2022.
Venture capital investment in biotech reached $48 billion in 2021.
U.S. biotech VC funding $35 billion in 2023.
Global biotech M&A deals totaled $120 billion in 2023.
R&D spending in global biotech reached $200 billion in 2023.
U.S. biotech firms spent $120 billion on R&D in 2022.
Pharma R&D total $150 billion with biotech 40% in 2023.
Public biotech employment 300,000 in U.S. 2023.
Global biotech workforce 1 million+ in 2023.
U.S. biotech jobs grew 5% to 350,000 in 2023.
FDA approved 55 novel drugs in 2023.
Biotech drugs account for 40% of FDA approvals yearly.
Gene therapies approved: 10 cumulative by 2023.

The global biotech industry is massive, rapidly growing, and attracts huge investments.

Employment and Workforce

Public biotech employment 300,000 in U.S. 2023.
Global biotech workforce 1 million+ in 2023.
U.S. biotech jobs grew 5% to 350,000 in 2023.
California biotech employees 150,000.
PhD scientists in biotech 40% of workforce.
Women in biotech 50% of workforce in 2023.
Average biotech salary $120,000 in U.S.
EU biotech jobs 200,000 in 2023.
India biotech workforce 50,000 skilled.
Biotech manufacturing jobs 100,000 U.S.
Talent shortage in biotech 20% unfilled roles.
China biotech employees 300,000.
Entry-level biotech jobs grew 10% YoY.
Regulatory affairs roles 15% of biotech jobs.
Remote biotech jobs 25% post-pandemic.
Diversity in biotech leadership 30% underrepresented.
U.K. biotech workforce 40,000.
Bioinformatics specialists demand up 30%.
Clinical research associates 50,000 global.
Biotech layoffs 10,000 in 2023 downturn.
STEM graduates entering biotech 100,000 yearly U.S.
Average tenure in biotech 3.5 years.
Contract research jobs 20% of workforce.
Biotech hubs like Boston employ 80,000.
Upskilling programs trained 50,000 workers.
Global biotech job postings 200,000 in 2023.

Employment and Workforce Interpretation

While boasting over a million global workers and a promising influx of STEM talent, the biotech industry grapples with the ironic pinch of a severe talent shortage, all while trying to stabilize from notable layoffs and rapid job turnover.

Innovations and Approvals

FDA approved 55 novel drugs in 2023.
Biotech drugs account for 40% of FDA approvals yearly.
Gene therapies approved: 10 cumulative by 2023.
CAR-T approvals reached 6 by FDA in 2023.
mRNA vaccines: 2 approved for COVID by 2023.
CRISPR-based therapy first approved in 2023.
Orphan drug designations 500+ annually.
Biosimilars approved: 40 by FDA cumulative 2023.
Cell therapies in clinic: 1,500 trials.
Oncology biotech approvals 20 in 2023.
Breakthrough therapy designations 100+ yearly.
EMA biotech approvals 50 in 2023.
Rare disease approvals 20 novel in 2023.
Vaccine approvals 10 new platforms since 2020.
Precision oncology drugs 50 approved.
ADC approvals 12 cumulative by 2023.
Regenerative medicine approvals 5 advanced therapies.
Digital therapeutics FDA cleared 50+.
Biotech patents commercialized 1,000 yearly.
First AI-designed drug approved 2023.
BLA submissions 200+ to FDA yearly.
PMDA Japan biotech approvals 30 in 2023.
Success rate Phase I to approval 10% for biotech.
New molecular entities from biotech 30 in 2023.
CRISPR trials Phase III first entered 2023.
Bispecific antibodies approved 10 by 2023.

Innovations and Approvals Interpretation

The biotech industry, in a delightful show of audacity, has decided that the future of medicine is not a question but a to-do list, churning out everything from AI-designed drugs to cancer-hunting cells with the efficiency of a startup and the gravity of a mission to save lives.

Investment and Funding

Venture capital investment in biotech reached $48 billion in 2021.
U.S. biotech VC funding $35 billion in 2023.
Global biotech M&A deals totaled $120 billion in 2023.
IPOs in biotech raised $10 billion in 2023.
Private equity in biotech hit $15 billion in 2022.
EU biotech funding €12 billion in 2023.
Chinese biotech investments $20 billion in 2023.
Cancer biotech VC $12 billion in 2023.
Gene editing startups raised $4 billion in 2023.
Biotech follow-on offerings $8 billion in 2023.
Pandemic-related biotech funding peaked at $50 billion in 2020.
India biotech VC $2 billion in 2023.
AI-biotech crossover funding $3 billion in 2023.
Orphan drug investments $25 billion globally in 2022.
U.K. biotech sector funding £4 billion in 2023.
Series A biotech deals averaged $50 million in 2023.
M&A in cell therapy $10 billion in 2023.
Late-stage biotech funding down 20% to $20 billion in 2023.
Public biotech market cap $1.2 trillion in 2023.
Crowdfunding in biotech reached $500 million in 2023.
Government grants to biotech $30 billion globally in 2023.
Neuroscience biotech VC $5 billion in 2023.
Total U.S. life sciences VC $36 billion with biotech 80% share in 2023.
Biotech funding rounds over 1,000 in 2023.
Average biotech VC deal size $40 million in 2023.
Japan biotech investments ¥1 trillion in 2023.

Investment and Funding Interpretation

One might say the biotech industry is betting billions that your future health is worth a lot more than your current crypto portfolio.

Market Size and Growth

The global biotechnology market size was valued at USD 1.55 trillion in 2023.
The biotech market is projected to grow at a CAGR of 13.96% from 2024 to 2030.
U.S. biotech market revenue reached $200 billion in 2022.
European biotech sector generated €150 billion in revenue in 2023.
Asia-Pacific biotech market expected to reach $500 billion by 2028.
Global biopharma market size hit $465 billion in 2023.
CRISPR technology market valued at $3.4 billion in 2023.
Vaccine segment dominated biotech market with 30% share in 2023.
Gene therapy market projected to grow to $28.3 billion by 2030.
Regenerative medicine market size was $25.9 billion in 2023.
U.S. biotech submarket for oncology grew 15% YoY in 2023.
Global cell therapy market reached $8.2 billion in 2023.
Biotech market in India valued at $10 billion in 2023.
mRNA therapeutics market size $50 billion projected by 2028.
Precision medicine market hit $109 billion in 2023.
CAR-T cell therapy market $3.5 billion in 2023.
Global biotech tools market $85 billion in 2023.
Animal biotech market $27 billion by 2027 forecast.
Synthetic biology market $15.8 billion in 2023.
Biotech diagnostics market $95 billion in 2023.
North America holds 40% of global biotech market share in 2023.
Biotech market CAGR in China 20% from 2023-2030.
Industrial biotech market $40 billion by 2028.
Nucleic acid therapeutics $15 billion in 2023.
Biotech market recovery post-COVID grew 12% in 2022.
Stem cell market $12 billion projected by 2027.
Global biomanufacturing market $30 billion in 2023.
Oncology biotech segment $150 billion in 2023.
Rare disease biotech market $200 billion by 2030.
Digital biotech market $50 billion in 2023.
Global biotech revenue up 8% to $1.7 trillion in 2024 forecast.

Market Size and Growth Interpretation

While we’re still arguing about what’s for lunch, the biotech industry, now a multi-trillion dollar behemoth growing at a double-digit clip, has quietly decided the future of health, fuel, and food, with CRISPR as its pen, vaccines as its anchor, and every region from the U.S. to Asia-Pacific vying to bankroll the next miracle.

Research and Development

R&D spending in global biotech reached $200 billion in 2023.
U.S. biotech firms spent $120 billion on R&D in 2022.
Pharma R&D total $150 billion with biotech 40% in 2023.
CRISPR R&D investment $2 billion annually.
Gene therapy clinical trials 2,500+ ongoing in 2023.
NIH biotech grants $40 billion in 2023.
EU Horizon R&D for biotech €10 billion 2021-2027.
mRNA platform R&D accelerated post-COVID to $5 billion.
AI in biotech R&D $1 billion investment in 2023.
Oncology R&D pipeline 1,800 drugs in 2023.
Rare diseases R&D $50 billion annually.
Biomanufacturing R&D $10 billion in U.S. 2023.
Stem cell research funding $3 billion globally.
Synthetic biology R&D papers 10,000+ per year.
CAR-T R&D trials 1,000+ worldwide.
Precision medicine R&D $20 billion in 2023.
Vaccine R&D platforms 300+ active.
Neuroscience biotech R&D $15 billion.
Patent filings in biotech 50,000 annually.
Clinical trial participants in biotech 5 million yearly.
Phase III biotech trials 500+ in 2023.
Bioinformatics R&D spend $5 billion.
Organoid research investments doubling yearly.
Global clinical R&D costs $2.6 billion per drug.
U.S. biotech patents 20,000 issued in 2023.
Biotech R&D intensity 20% of revenue.

Research and Development Interpretation

The sheer scale of investment, from CRISPR’s precise billions to the vast clinical trial networks, paints a picture of an industry placing an astronomically expensive bet that our biological code is the ultimate fix-it manual for everything from rare diseases to the common cold.